Disc Medicine (IRON) Cash from Operations (2020 - 2026)
Disc Medicine (IRON) reported Cash from Operations of 62236000.0 for Q1 2026, down 50.42% year-over-year from 125515535.97 in Q1 2025, and down 43.73% on a QoQ basis from 43300000.0 in Q4 2025.
Disc Medicine (IRON) has 7 years of Cash from Operations data on file, last reported at 62236000.0 in Q1 2026.
- Quarterly Cash from Operations fell 50.42% year-over-year to 62236000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 201253000.0 (down 97.88% YoY) and the FY2025 annual result came in at 180393000.0, down 92.06% from the prior year.
- Cash from Operations fell to 62236000.0 in Q1 2026 per IRON's latest filing, from 43300000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 7476000.0 in Q3 2023 and bottomed at 62236000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 17796000.0 (2023), against an average of 26604058.82.
- The widest annual swing landed in 2022, when Cash from Operations surged 42.28%; it then tumbled 211.3% in 2025.
- Tracing IRON's Cash from Operations over 5 years: stood at 9665000.0 in 2022, then plunged by 84.13% to 17796000.0 in 2023, then sank by 54.94% to 27573000.0 in 2024, then tumbled by 57.04% to 43300000.0 in 2025, then plunged by 43.73% to 62236000.0 in 2026.
- Per Business Quant, the three latest IRON Cash from Operations figures stand at 62236000.0 (Q1 2026), 43300000.0 (Q4 2025), and 47799000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -62.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -62.24 Mn |
| Mar 31, 2026 | -62.24 Mn |
| Dec 31, 2025 | -43.30 Mn |
| Dec 31, 2025 | -43.30 Mn |
| Sep 30, 2025 | -47.80 Mn |
| Sep 30, 2025 | -47.80 Mn |
| Jun 30, 2025 | -47.92 Mn |
| Jun 30, 2025 | -47.92 Mn |
| Mar 31, 2025 | -41.38 Mn |
| Mar 31, 2025 | -41.38 Mn |
| Dec 31, 2024 | -27.57 Mn |
| Dec 31, 2024 | -27.57 Mn |
| Sep 30, 2024 | -17.36 Mn |
| Sep 30, 2024 | -17.36 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Jun 30, 2024 | -15.39 Mn |
| Mar 31, 2024 | -33.60 Mn |
| Mar 31, 2024 | -33.60 Mn |
| Dec 31, 2023 | -17.80 Mn |
| Dec 31, 2023 | -17.80 Mn |
| Sep 30, 2023 | -7.48 Mn |
| Sep 30, 2023 | -7.48 Mn |
| Jun 30, 2023 | -12.72 Mn |
| Jun 30, 2023 | -12.72 Mn |
| Mar 31, 2023 | -35.47 Mn |
| Mar 31, 2023 | -35.47 Mn |
| Dec 31, 2022 | -9.67 Mn |
| Dec 31, 2022 | -9.67 Mn |
| Sep 30, 2022 | -9.69 Mn |
| Sep 30, 2022 | -9.69 Mn |
| Jun 30, 2022 | -9.19 Mn |
| Jun 30, 2022 | -9.19 Mn |
| Mar 31, 2022 | -13.70 Mn |
| Mar 31, 2022 | -13.70 Mn |
| Dec 31, 2021 | 19.50 Mn |
| Dec 31, 2021 | 19.50 Mn |
| Sep 30, 2021 | -16.10 Mn |
| Sep 30, 2021 | -16.10 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Mar 31, 2021 | -15.01 Mn |
| Mar 31, 2021 | -15.01 Mn |
| Dec 31, 2020 | -416,411.00 |
| Dec 31, 2020 | -416,411.00 |
| Sep 30, 2020 | -190,568.00 |
| Sep 30, 2020 | -190,568.00 |
| Jun 30, 2020 | -7.03 Mn |
| Jun 30, 2020 | -7.03 Mn |
| Mar 31, 2020 | -9.88 Mn |
| Mar 31, 2020 | -9.88 Mn |